peptidechats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Delta Sleep-Inducing Peptide (DSIP)

Also known as: DSIP, delta sleep-inducing peptide, delta-sleep-inducing peptide, WAGGDASGE, Deltaran

Neuropeptide / Regulatory peptide (nonapeptide)

Ask about Delta Sleep-Inducing Peptide (DSIP) in chat →

What it is

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide with multifunctional regulatory activity. It was originally isolated from rabbit cerebral venous blood in 1977 and initially characterized as a sleep-promoting factor, though its link to sleep has not been definitively established. Its biosynthetic origin remains obscure; no DSIP gene or protein precursor has been confirmed, though JmjC-domain-containing histone demethylases (JMJD1B gene) have been proposed as possible precursors based on sequence homology (PMID 21262293; PMID 24397026). DSIP has been shown to influence oxidative phosphorylation in rat brain mitochondria, significantly increasing the rate of phosphorylated respiration (V3) and the respiratory control ratio. It modulates neurotransmitter systems including Met-enkephalin release, spinal noradrenergic pathways mediating antinociception, and GABAergic Cl⁻ flux. DSIP also affects thermoregulation via 5-HT1A and dopaminergic mechanisms (PMID 8015981; PMID 2322843). Stress-protective and adaptive activity has been described across multiple stressor types. DSIP displays a saturable, high-affinity transport mechanism at the blood-brain barrier, and also enters CSF to a slight or moderate extent in intact form. It is rapidly degraded in blood, primarily by cleavage of the N-terminal tryptophan via aminopeptidases (PMID 3628078; PMID 8474631). Plasma DSIP-like immunoreactivity decreases at the initiation of sleep. A phosphorylated analogue (P-DSIP, phosphorylated at Ser7) shows slower degradation and different pharmacodynamic properties (PMID 3628078; PMID 2496423). Recovery-enhancing and circadian/mitochondrial regulatory roles are noted in orthopaedic-relevant reviews.

Class: Neuropeptide / Regulatory peptide (nonapeptide)

What it's studied for

  • Sleep promotion / insomnia treatment Human observational
    • Acute intravenous DSIP (25 nmol/kg) in 6 middle-aged chronic insomniacs produced longer sleep duration, higher sleep quality, fewer interruptions, slightly more REM sleep, with no daytime sedation or other side effects. PMID 7028502 Schneider-Helmert & Schoenenberger (1981) Experientia
    • In 6 healthy volunteers (double-blind cross-over), DSIP (25 nmol/kg IV, morning) increased total sleep time by 59% within 130 min. Delayed effects included shorter sleep onset and better sleep efficiency. Well-tolerated, no psychologic, physiologic, or biochemical side effects. PMID 6895513 Schneider-Helmert et al. (1981) Int J Clin Pharmacol Ther Toxicol
    • Five human studies with single and repeated IV DSIP injections; complete normalization of disturbed sleep achieved after four consecutive injections to insomniacs. Slow injection was essential. Compatibility was good. PMID 6689058 Schneider-Helmert & Schoenenberger (1983) Neuropsychobiology
    • Double-blind studies in insomniacs showed improvement of sleep following single dose treatments and repeated injections. A case study described DSIP efficacy on narcolepsy. PMID 3758119 Schneider-Helmert (1984) Eur Neurol
    • Single injections of 25 nmol/kg improved sleep in insomniacs; repeated administration showed buildup with normalization of sleep structure after four administrations. PMID 6391925 Schneider-Helmert (1984) Eur Neurol
    • 18 chronic insomniacs received 6 × 30 nmol/kg IV over one week. Middle-aged insomniacs normalized sleep by end of administration; elderly insomniacs reached normalization during follow-up. Effects correlated with degree of sleep disturbance. PMID 3792404 Schneider-Helmert (1986) Eur Neurol
    • Open study: 7 patients with severe insomnia received 10 injections of DSIP. In all but 1, sleep normalized for 3–7 months follow-up. PMID 6391926 Kaeser (1984) Eur Neurol
    • Case report: DSIP treatment advanced main sleep phase by 5 hours in a patient with chronic delayed sleep phase insomnia and flunitrazepam dependence, with complete benzodiazepine withdrawal. PMID 3582201 Schneider-Helmert et al. (1987) Dtsch Med Wochenschr
  • Narcolepsy treatment Human observational
    • Repeated DSIP injections in a 35-year-old male narcoleptic reduced frequency of sleep attacks and increased activity, alertness, and performance during daytime. Sleep period was compressed with enhanced REM sleep. PMID 6548968 Schneider-Helmert (1984) Eur Neurol
  • Alcohol and opiate withdrawal Human observational
    • DSIP administered IV to 107 inpatients with alcohol (n=47) or opiate (n=60) withdrawal. Clinical symptoms and signs disappeared or improved markedly in ~97% of opiate and ~87% of alcohol addicts. Tolerance was good; headaches reported by a few patients. Anxiety was slower to decrease. PMID 6548969 Dick et al. (1984) Eur Neurol
  • Chronic pain treatment Human observational
    • Pilot study in 7 patients with migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain. DSIP IV on 5 consecutive days followed by 5 injections every 48–72 h significantly lowered pain levels in 6 of 7 patients. Simultaneous significant reduction of comorbid depressive states was observed. PMID 6548970 Larbig et al. (1984) Eur Neurol
  • Antiepileptic / anticonvulsant activity Animal studies only
    • DSIP and analogue DSIP-12 (i.p.) significantly increased delta and theta frequency bands and decreased incidence, mean seizure grade, and duration of metaphit-induced convulsions in rats. DSIP-12 was more efficient than DSIP. PMID 15911358 Stanojlović et al. (2005) Seizure
    • In 720 male rats, DSIP produced higher pentylenetetrazol seizure thresholds during night periods and offered improved protection during night hours compared to saline control. PMID 8483798 Yehuda & Mostofsky (1993) Peptides
    • DSIP and related peptide KND showed anticonvulsive effects in vivo in rats. PMID 24397026 Mikhaleva et al. (2013) Bioorg Khim
  • Stress protection / antistress Mixed
    • Intraperitoneal DSIP (30 µg/kg) reduced stress-induced Fos expression in pPVN and limbic regions, particularly in rats predisposed to emotional stress. PMID 22432135 Sudakov et al. (2001) Stress
    • DSIP is described as an antistress oligopeptide increasing resistance to stressful impacts in humans, alongside substance P, beta-endorphin, and semax. PMID 19140465 Sudakov (2008) Vestn Ross Akad Med Nauk
    • DSIP (25 µg/kg IV) prevented hyposomnia after a stressful situation in rabbits. PMID 6548967 Scherschlicht et al. (1984) Eur Neurol
  • Neuroprotection / stroke recovery Animal studies only
    • Intranasal DSIP (120 µg/kg, 8 days) in SD rats with focal stroke (MCAO model) led to significantly accelerated recovery of motor functions in the rotarod test, though infarction volume reduction was not significant. PMID 34500605 Tukhovskaya et al. (2021) Molecules
  • Mitochondrial respiration enhancement / hypoxia protection Animal studies only
    • DSIP significantly increased V3 (phosphorylated respiration rate), enhanced respiratory control ratio, and rate of ADP phosphorylation in rat brain mitochondria in vitro. Pretreatment with DSIP (120 µg/kg i.p.) prior to hypoxia in rats completely inhibited hypoxia-induced reduction of mitochondrial respiratory activity PMID 12668217 Khvatova et al. (2003) Peptides
  • Antioxidant / detoxification (DSIP analogues) Animal studies only
    • 16 DSIP analogues exhibited considerable direct antioxidative activity in vitro. Analogue ID-6 showed AOA comparable to vitamin C and β-carotene and the most pronounced detoxifying effect against cisplatin in mice, reducing animal death from acute cisplatin toxicity to 17% versus 50–67% in controls. PMID 25898718 Mikhaleva et al. (2014) Bioorg Khim
  • Antinociception / pain modulation Animal studies only
    • DSIP (1 pM–1 nM) significantly stimulated calcium-dependent release of immunoreactive Met-enkephalin from rat lower brainstem slices, suggesting indirect action on opioid receptors for antinociceptive effects. PMID 2706459 Nakamura et al. (1989) Brain Res
    • ICV DSIP antinociceptive effects in mice were significantly reduced by reserpine (monoamine depletion) and antagonized by intrathecal phentolamine or yohimbine (alpha-adrenergic blockers), but not methysergide. Implicates descending noradrenergic systems. PMID 2713670 Nakamura et al. (1989) Brain Res
  • Sleep EEG and CSF correlates in psychiatric/neurological disease Human observational
    • CSF DSIP-LI in 15 drug-free male schizophrenic subjects was significantly correlated with stage 3 sleep and delta sleep during the first NREM period and negatively with stage 2% sleep on polysomnography. PMID 1475566 van Kammen et al. (1992) Sleep
    • CSF DSIP-LI was significantly decreased in patients with mid-to-late stage Alzheimer's dementia, multi-infarct dementia, Parkinson's disease, vascular disease, and communicating hydrocephalus compared to age-matched controls. DSIP-LI positively correlated with age in both control groups. PMID 2448424 Ernst et al. (1987) J Neurol
    • Plasma DSIP-LI was significantly elevated in suicidal patients with major depressive disorder (MDD, p<0.005). Significant correlation between predexamethasone cortisol and predexamethasone DSIP-LI in healthy controls suggested glucocorticoid involvement in DSIP regulation. PMID 9606527 Westrin et al. (1998) Biol Psychiatry
  • Sleep promotion via fusion peptide (DSIP-CBBBP) — preclinical Animal studies only
    • DSIP fused with a blood-brain barrier crossing peptide (DSIP-CBBBP) expressed in Pichia pastoris showed better restorative effect than DSIP alone on neurotransmitter imbalance (5-HT, glutamate, dopamine, melatonin) and enhanced sleep in a PCPA-induced insomnia mouse model. PMID 39444618 Mu et al. (2024) Front Pharmacol

Community-reported dosing

RouteDoseFrequency / DurationPopulation / contextSource tier
Intravenous25 nmol/kg body weightSingle acute injectionhumanResearch PMID 7028502
Slow intravenous infusion25 nmol/kgSingle morning infusionhumanResearch PMID 6895513
Intravenous injection25 nmol/kg body weightSingle injections; repeated administrations describedhumanResearch PMID 6391925
Intravenous6 × 30 nmol/kg body weightOne week (6 injections)humanResearch PMID 3792404
IntravenousNot specified (multiple injections; opiate addicts required higher number of injections than alcoholics)Variable, clinical coursehumanResearch PMID 6548969
Intravenous5 injections on consecutive days, then 5 injections every 48–72 h (dose not specified in abstract)~2 weekshumanResearch PMID 6548970
IntravenousNot fully specified; single and repeated IV injections studiedSingle and repeated administrationshumanResearch PMID 6689058
Intravenous; subcutaneous25 µg/kg IV; 1 mg/kg subcutaneous (rabbits); 25 µg/kg IV, 100 µg/kg subcutaneous (cats); 25.5 µg/kg IV and doses beyond 85 µg/kg subcutaneous (morphine-dependent mice)Single doses (various experiments)animalResearch PMID 6548967
Intraperitoneal30 µg/kgSingle intraperitoneal injectionanimalResearch PMID 22432135
Intraperitoneal120 µg/kgSingle pretreatment prior to hypoxiaanimalResearch PMID 12668217
Intranasal120 µg/kg8 days (applied 60 min prior to occlusion and for 7 days after reperfusion)animalResearch PMID 34500605
Intracerebroventricular infusion0.5 nmol P-DSIP (phosphorylated analogue); doses ranging 0.025–25 nmol testedContinued 10-h nocturnal intracerebroventricular infusionanimalResearch PMID 2496423
Intracerebroventricular (lateral ventricle)Peptides injected into lateral ventricle of cerebrum (doses not fully specified in abstract)Single injections, 7–12 h monitoringanimalResearch PMID 45118
Not specified (i.p. context for apomorphine model)Minimal effective dose 10 ng; maximal effective dose 1 µg (dose-response relationship: inverted bell-shape)Single injectionanimalResearch PMID 2322843
In vitro (superfused brain slices)1 pM–1 nMIn vitroin_vitroResearch PMID 2706459
subcutaneous injection100 mcgonce daily, administered 30-60 minutes before sleepbiohackers and sleep-optimization enthusiasts seeking improved sleep quality[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200 mcgonce daily, administered 30-60 minutes before sleepbiohackers and sleep-optimization enthusiasts who found 100 mcg insufficient[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection500 mcgonce daily, administered before sleepexperienced biohackers and heavier users seeking pronounced sedative/sleep effects[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200-500 mcgonce daily before sleep, for 5 days on / 2 days offbiohackers running longer-term DSIP cycles for chronic sleep issues or stress management[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection100 mcgonce daily in the morningbiohackers and individuals using DSIP for stress and anxiety reduction rather than direct sleep induction[S] Claude Sonnet 4.6 — synthesized from aggregate training data
intranasal200 mcgonce daily, 30-60 minutes before sleepbiohackers who prefer needle-free administration for sleep optimization[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection100-200 mcgonce daily before sleep, stacked with other peptidesbiohackers stacking DSIP with peptides such as Epithalon or Selank for combined sleep and recovery/anti-aging effects[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection300 mcgonce daily before sleepbiohackers seeking a mid-range dose between standard 200 mcg and higher 500 mcg options[S] Claude Sonnet 4.6 — synthesized from aggregate training data

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

  • Headaches reported by a few patients during intravenous DSIP treatment for alcohol and opiate withdrawal (107-patient clinical study). PMID 6548969
  • Slight arousing/activating effect (rather than sedating) observed in the first hour after intravenous injection in human insomnia studies; sleep-promoting effects only emerged in the second hour. PMID 7028502
  • Rapid degradation in blood (release of tryptophan, rate dependent on temperature and species) may contribute to variable and inconsistent in vivo effects. PMID 3628078
  • Bell-shaped dose-response relationships reported in animal studies across multiple experimental settings; doses outside the effective range were ineffective or produced different effects. PMID 6548967
  • DSIP analogue [beta-Ala2]DSIP significantly suppressed sleep in rabbits in contrast to the sleep-promoting effects of parent DSIP or other analogues, suggesting that structural modifications can reverse biological activity. PMID 11525128

Contraindications

  • No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify specific clinical contraindications for DSIP administration. PMID 16539679

References

  1. [1] PMID 7028502 — Acute intravenous DSIP (25 nmol/kg) in 6 middle-aged chronic insomniacs produced longer sleep duration, higher sleep quality, fewer interruptions, slightly more
  2. [2] PMID 6895513 — In 6 healthy volunteers (double-blind cross-over), DSIP (25 nmol/kg IV, morning) increased total sleep time by 59% within 130 min. Delayed effects included shor
  3. [3] PMID 6689058 — Five human studies with single and repeated IV DSIP injections; complete normalization of disturbed sleep achieved after four consecutive injections to insomnia
  4. [4] PMID 3758119 — Double-blind studies in insomniacs showed improvement of sleep following single dose treatments and repeated injections. A case study described DSIP efficacy on
  5. [5] PMID 6391925 — Single injections of 25 nmol/kg improved sleep in insomniacs; repeated administration showed buildup with normalization of sleep structure after four administra
  6. [6] PMID 3792404 — 18 chronic insomniacs received 6 × 30 nmol/kg IV over one week. Middle-aged insomniacs normalized sleep by end of administration; elderly insomniacs reached nor
  7. [7] PMID 6391926 — Open study: 7 patients with severe insomnia received 10 injections of DSIP. In all but 1, sleep normalized for 3–7 months follow-up.
  8. [8] PMID 3582201 — Case report: DSIP treatment advanced main sleep phase by 5 hours in a patient with chronic delayed sleep phase insomnia and flunitrazepam dependence, with compl
  9. [9] PMID 6548968 — Repeated DSIP injections in a 35-year-old male narcoleptic reduced frequency of sleep attacks and increased activity, alertness, and performance during daytime.
  10. [10] PMID 6548969 — DSIP administered IV to 107 inpatients with alcohol (n=47) or opiate (n=60) withdrawal. Clinical symptoms and signs disappeared or improved markedly in ~97% of
  11. [11] PMID 6548970 — Pilot study in 7 patients with migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain. DSIP IV on 5 consecutive days followed by 5 injections eve
  12. [12] PMID 15911358 — DSIP and analogue DSIP-12 (i.p.) significantly increased delta and theta frequency bands and decreased incidence, mean seizure grade, and duration of metaphit-i
  13. [13] PMID 8483798 — In 720 male rats, DSIP produced higher pentylenetetrazol seizure thresholds during night periods and offered improved protection during night hours compared to
  14. [14] PMID 24397026 — DSIP and related peptide KND showed anticonvulsive effects in vivo in rats.
  15. [15] PMID 22432135 — Intraperitoneal DSIP (30 µg/kg) reduced stress-induced Fos expression in pPVN and limbic regions, particularly in rats predisposed to emotional stress.
  16. [16] PMID 19140465 — DSIP is described as an antistress oligopeptide increasing resistance to stressful impacts in humans, alongside substance P, beta-endorphin, and semax.
  17. [17] PMID 6548967 — DSIP (25 µg/kg IV) prevented hyposomnia after a stressful situation in rabbits.
  18. [18] PMID 34500605 — Intranasal DSIP (120 µg/kg, 8 days) in SD rats with focal stroke (MCAO model) led to significantly accelerated recovery of motor functions in the rotarod test,
  19. [19] PMID 12668217 — DSIP significantly increased V3 (phosphorylated respiration rate), enhanced respiratory control ratio, and rate of ADP phosphorylation in rat brain mitochondria
  20. [20] PMID 25898718 — 16 DSIP analogues exhibited considerable direct antioxidative activity in vitro. Analogue ID-6 showed AOA comparable to vitamin C and β-carotene and the most pr
  21. [21] PMID 2706459 — DSIP (1 pM–1 nM) significantly stimulated calcium-dependent release of immunoreactive Met-enkephalin from rat lower brainstem slices, suggesting indirect action
  22. [22] PMID 2713670 — ICV DSIP antinociceptive effects in mice were significantly reduced by reserpine (monoamine depletion) and antagonized by intrathecal phentolamine or yohimbine
  23. [23] PMID 1475566 — CSF DSIP-LI in 15 drug-free male schizophrenic subjects was significantly correlated with stage 3 sleep and delta sleep during the first NREM period and negativ
  24. [24] PMID 2448424 — CSF DSIP-LI was significantly decreased in patients with mid-to-late stage Alzheimer's dementia, multi-infarct dementia, Parkinson's disease, vascular disease,
  25. [25] PMID 9606527 — Plasma DSIP-LI was significantly elevated in suicidal patients with major depressive disorder (MDD, p<0.005). Significant correlation between predexamethasone c
  26. [26] PMID 39444618 — DSIP fused with a blood-brain barrier crossing peptide (DSIP-CBBBP) expressed in Pichia pastoris showed better restorative effect than DSIP alone on neurotransm
  27. [27] PMID 2496423 — 0.5 nmol P-DSIP (phosphorylated analogue); doses ranging 0.025–25 nmol tested Intracerebroventricular infusion (animal)
  28. [28] PMID 45118 — Peptides injected into lateral ventricle of cerebrum (doses not fully specified in abstract) Intracerebroventricular (lateral ventricle) (animal)
  29. [29] PMID 2322843 — Minimal effective dose 10 ng; maximal effective dose 1 µg (dose-response relationship: inverted bell-shape) Not specified (i.p. context for apomorphine model) (
  30. [30] PMID 3628078 — Rapid degradation in blood (release of tryptophan, rate dependent on temperature and species) may contribute to variable and inconsistent in vivo effects.
  31. [31] PMID 11525128 — DSIP analogue [beta-Ala2]DSIP significantly suppressed sleep in rabbits in contrast to the sleep-promoting effects of parent DSIP or other analogues, suggesting
  32. [32] PMID 16539679 — No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify specific clinical contraindications for DSIP admin
  33. [33] PMID 21262293 — in-prose reference
  34. [34] PMID 1666953 — in-prose reference
  35. [35] PMID 8015981 — in-prose reference
  36. [36] PMID 2547200 — in-prose reference
  37. [37] PMID 6304442 — in-prose reference
  38. [38] PMID 8474631 — in-prose reference
  39. [39] PMID 8745061 — in-prose reference
  40. [40] PMID 41490200 — in-prose reference
  41. [41] PMID 6145137 — in-prose reference
Dial in your dose in chat →

Related peptides

EpitalonSynthetic tetrapeptide / pineal gland peptide bioregulatorCJC-1295Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone SecretagogueFollistatin 315Endogenous glycoprotein / activin-binding protein (TGF-β superfamily antagonist)